Mark your calendars! The OMPRN Pathology Matters meeting is going virtual again this year on October 25 and 26. Stay tuned for scheduling info and speaker announcements. #pathology#cancer#conference
Just wrapped on a successful first day of the 2021 Pathology Matters virtual meeting! Day 2 starts tomorrow at 10:55 AM EST. See you once more on Zoom tomorrow!
Meeting info on the OMPRN website: https://t.co/ytTKxfIxNy
#pathology#cancer#conference#PathMatters2021
Day 1 of the 2021 Pathology Matters virtual meeting kicks off at 1:30 PM today! To all our registrants, we will see you soon on Zoom! Meeting info on the OMPRN website: https://t.co/ytTKxfIxNy
#pathology#cancer#conference#PathMatters2021
Little reminder: 💲OMPRN’s 6th grant competition is accepting applications! Funding support for Ontario-based pathology researchers. $50K or $75K for 1 year - applications due Nov 1, 2021 details: https://t.co/CCgLt14eFy #pathology#research#funding
💲OMPRN’s 6th round of Cancer Pathology Translational Research Grants (CPTRG) now accepting applications! Funding support for Ontario-based pathology researchers. $50K or $75K for 1 year - applications due Nov 1, 2021 details: https://t.co/CCgLt14eFy #pathology#research#funding
Hi everyone! Our colleagues in Toronto would like you to know about this year's Pathology Update Digital Conference (Nov. 4-5, 2021) on Head and Neck Pathology: Practical Approach and Emerging Issues. More info and registration details: https://t.co/lh6Dtmcail
#pathology#CPD
Hi, followers! Our friends at OICR BioLab would like to let you know about a Zoom Tech Talk on IsoPlexis single-cell omits technology next week 🔬.
More info: https://t.co/vXlQUGau4F
Sign up: https://t.co/W98d2ESuUZ
#Technology#PersonalizedMedicine#TumourHeterogeneity
Join us next week at @OICR_news@JLABS symposium on the exciting area of #epigenetics in the origins of cancer, early cancer detection, and therapies.
Dr. Andrew Feinberg, @decarvalho_lab + others, moderated by @spaiglass.
This is going to be great!
https://t.co/7QcjLcEELw
Pathology and Molecular Medicine congratulates our own Dr Harriet Feilotter as new Director of OMPRN. An exciting new chapter for molecular pathology in Ontario!
📢 @OICR_news announces new OMPRN Director, Dr. Harriet Feilotter from @queensu.
🎉 Please join us in congratulating Dr. Feilotter on her new role as OMPRN Director!
Read the announcement letter here: https://t.co/icCAnacdqq
#cancer#molecular#pathology#leadership
Epigenetics is one of the most exciting fields in cancer research today and is revolutionizing how we understand and approach cancer.
Join @JLABS & @OICR_News on June 1 to hear from leading researchers in this space. Grab your ticket! https://t.co/nBjofYnsHy
Our friends in the @TILsWorkGroup want to better understand TILs in breast cancer. Help by completing their questionnaire: https://t.co/L1b8kUPyq4
Open to pathologists, oncologists, patients, industry, others - feel free to share with your colleagues!
#TILS#BreastCancer
Dear followers, OICR is seeking a new OMPRN Director. Follow this link to learn more: https://t.co/JVfLAuIbMc
Please share this message with your interested colleagues. #ontario#cancer#pathology#leadership#careers
Today is #WorldCancerDay. We are thankful for all of our partners in cancer research: patients, caregivers, clinicians, collaborators and funders. Together, we are making progress against cancer. Read how OICR is contributing to this global effort https://t.co/2p47YrspUc
#WCD2021
Registration for Falcons’ Fortunes virtual pitch competition is now open! On February 4, #WorldCancerDay, watch 6 finalists pitch #OntarioMade oncology research ideas for a chance at $50k #InnovateON#pitchcomp Register at https://t.co/Rm2r3nIWr2
OICR's new Patient and Family Advisory Council is looking for patient partners, their family members and caregivers with cancer experiences, an interest in cancer research and a background in patient partnership. The deadline to apply is Feb 22. https://t.co/qtVnSiM6Hf
Ontario cancer researchers and clinicians - please help spread the word! 👇
@CDNCancerTrials recently launched a clinical trial for cancer patients at risk from #COVID19, focused on strengthening the immune system to prevent severe infections. https://t.co/AGJHw1o3xu